MacroGenics shares are trading higher after the company reported better-than-expected Q4 financial results. Also, Barclays maintained its Overweight rating and raised its price target from $3 to $4.

SBIO

<p>MacroGenics shares are trading higher after the company reported better-than-expected Q4 financial results. Also, Barclays maintained its Overweight rating and raised its price target from $3 to $4.</p>

benzinga_article

iShares Global Healthcare

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Macrogenics

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

VG Health

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bear 3X

News